Routine board appointment — no immediate trading catalyst. Monitor for any future partnership announcements given Simon's business development background, but the filing itself is not actionable.
Price Chart
Executive Summary
Serina Therapeutics appointed Farrell Simon, Pharm.D., to its Board of Directors, effective July 22, 2026. Dr. Simon, currently Chief Commercial Officer at Trevi Therapeutics (Nasdaq: TRVI), brings commercial strategy and business development experience and will also serve on the Audit and Compensation Committees. This is a routine board addition with no material financial impact or red flags.
Key Facts
- Farrell Simon appointed to Serina's Board of Directors effective July 22, 2026.
- Dr. Simon also appointed to the Audit Committee and Compensation Committee.
- Simon is Chief Commercial Officer at Trevi Therapeutics (Nasdaq: TRVI) and previously held senior roles at Pfizer.
- No departure or unexpected C-suite change; replacement is a newly added board member.
- Compensation will follow the company's standard Director Compensation Policy.
Financial Impact
No direct financial impact; standard director compensation per policy.
Risk Factors
- No material risks disclosed; standard forward-looking statement risks for a clinical-stage biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001708599-26-000043 |
| Document: farrellsimon_serinaxboddra.htm | 0001708599-26-000043 |
| Document: 0001708599-26-000043-index-headers.html | 0001708599-26-000043 |
| Document: 0001708599-26-000043-index.html | 0001708599-26-000043 |
| Document: 0001708599-26-000043.txt | 0001708599-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $2.57 $2.16 | ▼ −15.95% | ▼ −14.86% | $1.71 (−33.46%) |
Jul 23, 2026 13w ago | Press Release | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.71 (−18.18%) |
Jul 22, 2026 13w ago | 8-K | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.71 (−18.18%) |
Jun 4, 2026 20w ago | EFFECT | $1.86 $1.81 | ▲ +2.69% | ▲ +0.14% | $1.71 (+8.06%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▼ −0.56% | ▼ −1.02% | $1.71 (−5.00%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▲ +0.56% | ▲ +1.02% | $1.71 (+5.00%) |
May 22, 2026 22w ago | S-3 | $1.92 $1.81 | ▲ +5.73% | ▲ +6.81% | $1.71 (+10.94%) |
Mar 27, 2026 30w ago | 10-K/A | $2.27 $2.15 | ▼ −5.29% | ▼ −9.15% | $1.71 (−24.67%) |
Mar 25, 2026 30w ago | Press Release | $2.61 $2.12 | ▼ −18.77% | ▼ −20.41% | $1.71 (−34.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers